Abstract
Inter-individual variations in response to pharmacotherapy such as adverse effects, treatment resistance and toxicities affect all patient populations. Multidrug resistance associated proteins (MRPs) work as efflux pumps for many xenobiotics and endogenous substances and hence, can affect the drug concentration at the target site which governs therapeutic response. Genetic polymorphisms of the MRPs can lead to an over- or under-expression of these transporter proteins. These polymorphisms can therefore play an integral role in drug disposition and therapeutic outcomes via pharmacokinetic and pharmacodynamic changes. These changes may cause drug-drug interactions, treatment resistance and/or toxicity. Overexpression of certain MRPs is thought to correlate with multidrug resistance in pharmacotherapy, especially with anticancer drugs. It is also evident that some genetic variants linked with MRP genes can lead to disease states such as pseudoxanthoma elasticum. With further research, more definitive functional characterization of MRPs and the understanding of this relationship with genetic polymorphisms can be achieved. This article highlights the genetic polymorphisms of MRPs and their clinical implications with an emphasis on MRP1-4. It also provides an insight into the role that these proteins can play in disease states and toxicities as well as the implications for future research and patient management.
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenomics of Human Multidrug Resistance Associated Proteins
Volume: 6 Issue: 2
Author(s): Shu-Feng Zhou and Jana Fulcher
Affiliation:
Abstract: Inter-individual variations in response to pharmacotherapy such as adverse effects, treatment resistance and toxicities affect all patient populations. Multidrug resistance associated proteins (MRPs) work as efflux pumps for many xenobiotics and endogenous substances and hence, can affect the drug concentration at the target site which governs therapeutic response. Genetic polymorphisms of the MRPs can lead to an over- or under-expression of these transporter proteins. These polymorphisms can therefore play an integral role in drug disposition and therapeutic outcomes via pharmacokinetic and pharmacodynamic changes. These changes may cause drug-drug interactions, treatment resistance and/or toxicity. Overexpression of certain MRPs is thought to correlate with multidrug resistance in pharmacotherapy, especially with anticancer drugs. It is also evident that some genetic variants linked with MRP genes can lead to disease states such as pseudoxanthoma elasticum. With further research, more definitive functional characterization of MRPs and the understanding of this relationship with genetic polymorphisms can be achieved. This article highlights the genetic polymorphisms of MRPs and their clinical implications with an emphasis on MRP1-4. It also provides an insight into the role that these proteins can play in disease states and toxicities as well as the implications for future research and patient management.
Export Options
About this article
Cite this article as:
Zhou Shu-Feng and Fulcher Jana, Pharmacogenomics of Human Multidrug Resistance Associated Proteins, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020134
DOI https://dx.doi.org/10.2174/1875692110806020134 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Pantothenate Kinase-Associated Neurodegeneration
Current Drug Targets Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews The Influence of a Half-Marathon Race Upon Cardiac Troponin T Release in Adolescent Runners
Current Medicinal Chemistry Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Emerging Concepts in Diabetes: Mitochondrial Dynamics and Glucose Homeostasis
Current Diabetes Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner
Current HIV Research The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases
Reviews on Recent Clinical Trials Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design